Journal: British Journal of Clinical Pharmacology

Article Title: Repaglinide-gemfibrozil drug interaction: inhibition of repaglinide glucuronidation as a potential additional contributing mechanism

doi: 10.1111/j.1365-2125.2010.03772.x

Figure Lengend Snippet: The inhibitory effects of gemfibrozil and itraconazole on the depletion of repaglinide (0.1 µ m initial concentration) formation of M2, M4 and repaglinide glucuronide (RG) in fresh hepatocyte incubations (1 million cells ml −1 )

Article Snippet: Rifamycin SV was purchased from MP Biomedicals (Solon, OH).

Techniques: Concentration Assay, Inhibition

Journal: Journal of Travel Medicine

Article Title: Development of a new travellers’ diarrhoea clinical severity classification and its utility in confirming rifamycin-SV efficacy

doi: 10.1093/jtm/taad043

Figure Lengend Snippet: MCA: association and clusters (pooled rifamycin-SV Studies 1 and 2, ITT population)

Article Snippet: June S. Almenoff is an Employee of RedHill Biopharma, which markets rifamycin SV in the US.

Techniques:

Journal: Journal of Travel Medicine

Article Title: Development of a new travellers’ diarrhoea clinical severity classification and its utility in confirming rifamycin-SV efficacy

doi: 10.1093/jtm/taad043

Figure Lengend Snippet: Assessment of TLUS based on The TD clinical severity category (pooled rifamycin-SV Studies 1 and 2, ITT population)

Article Snippet: June S. Almenoff is an Employee of RedHill Biopharma, which markets rifamycin SV in the US.

Techniques:

Journal: Journal of Travel Medicine

Article Title: Development of a new travellers’ diarrhoea clinical severity classification and its utility in confirming rifamycin-SV efficacy

doi: 10.1093/jtm/taad043

Figure Lengend Snippet: Reassessment of rifamycin-SV efficacy in two Phase 3 studies based on TD severity categories: median TLUS [h] by baseline disease severity

Article Snippet: June S. Almenoff is an Employee of RedHill Biopharma, which markets rifamycin SV in the US.

Techniques: Comparison

Journal: Molecules

Article Title: Recent Advances in Macrocyclic Drugs and Microwave-Assisted and/or Solid-Supported Synthesis of Macrocycles

doi: 10.3390/molecules27031012

Figure Lengend Snippet: Key attributes, physiochemical properties, and PK parameters [ 32 , 33 ] of FDA-approved macrocyclic drugs since 2014.

Article Snippet: Aemcolo (rifamycin SV) , Antibacterial , Protein synthesis inhibitor by binding to the β-subunit of bacterial DNA-dependent RNA polymerase , 697.77 , 1.52 , 13 , 6 , 201 , 388 mg (two tablets) PO twice daily , , <0.1 , 80 , , Not expected , , 86 , Aries Pharmaceuticals, Inc. , 16 November 2018.

Techniques: Protein Binding, Protease Inhibitor, Inhibition, Disruption, Membrane, Binding Assay, Clinical Proteomics, Control, Diagnostic Assay, Imaging